ClinicalTrials.gov
ClinicalTrials.gov Menu

Supplementary Vitamin B12 Effects on Elevated Homocysteine Levels of Vegetarians - Clinical Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01661309
Recruitment Status : Completed
First Posted : August 9, 2012
Last Update Posted : May 20, 2014
Sponsor:
Information provided by (Responsible Party):
Derek Obersby, University of West London

Brief Summary:
Vegetarians are known to be deficient in vitamin B12, due to a lack or absence of dietary animal produce, which can elevate homocysteine. There is strong evidence indicating that elevated plasma total homocysteine (tHcy) is a contributor to chronic conditions, such as primary cardiovascular disease (CVD). The study hypothesis is: There will be a significant decrease in plasma tHcy of vegetarians following the intervention by supplementary vitamin B12 (of the methylcobalamin type) and this will lead to a reduction of the risk of CVD.

Condition or disease Intervention/treatment Phase
Vitamin B12 Deficiency Dietary Supplement: Inactive lozenge Dietary Supplement: Methylcobalamin Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: To Critically Investigate and Evaluate Supplementary Vitamin B12 Effects on Elevated Homocysteine Levels of Vegetarians, Who May Have a Resultant Susceptibility to Hyperhomocysteinemia Related Diseases.
Study Start Date : March 2012
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014


Arm Intervention/treatment
Placebo Comparator: Inactive lozenge
Inactive lozenge containing 2mg sucrose dissolved in the mouth taken after a meal every other day for 16 weeks
Dietary Supplement: Inactive lozenge
Manufactured to mimic 1mg methylcobalamin lozenge

Dietary Supplement: Methylcobalamin
Aimed at reducing plasma tHcy.
Other Name: Vitamin B12

Experimental: Methylcobalamin
Methylcobalamin 1mg lozenge dissolved in the mouth following a meal taken every other day for 16 weeks.
Dietary Supplement: Inactive lozenge
Manufactured to mimic 1mg methylcobalamin lozenge

Dietary Supplement: Methylcobalamin
Aimed at reducing plasma tHcy.
Other Name: Vitamin B12




Primary Outcome Measures :
  1. Reduction of plasma total homocysteine of vegetarians [ Time Frame: 16 weeks per participant ]

Secondary Outcome Measures :
  1. Improvement in systolic and diastolic blood pressure [ Time Frame: 16 weeks per participant ]

Other Outcome Measures:
  1. Improvement in body mass index [ Time Frame: 16 weeks per participant ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Having a plasma tHcy >10 micromol/L
  • Not suffering from conditions as described in exclusion criteria.
  • Vegetarian for at least one year.
  • Not participating in a weight reducing diet.
  • Not consuming regularly vitamin B12 supplements.
  • Give written consent to participate in clinical trial and be fluent in English language.

Exclusion Criteria:

  • Having a plasma tHcy less or equal to 10 micromol/L.
  • Suffering from pernicious anemia or other vitamin B12 deficiency disease.
  • Undergone bowel surgery or suffer from gastrointestinal disease.
  • Pregnant, lactating or trying to conceive.
  • Smoker.
  • Alcohol intake regularly greater than official recommended daily units (i.e. 2 units female, 3 units male).
  • Consume large amounts of caffeine (regular consumption of >4 cups of strong tea or coffee per day).
  • Use of medications known to influence nutritional status.
  • Have genetic metabolic disease.
  • Suffer from renal failure, diabetes, thyroid disease, cardiovascular disease, dementia or cancer.
  • Have a known blood-borne infection (e.g. Hepatitis or HIV).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01661309


Locations
United Kingdom
University of West London
London, Middlesex, United Kingdom, TW8 9GA
Sponsors and Collaborators
University of West London
Investigators
Study Director: Amalia A Tsiami, PhD University of West London
Study Director: David C Chappell, PhD University of West London

Responsible Party: Derek Obersby, PhD Student, University of West London
ClinicalTrials.gov Identifier: NCT01661309     History of Changes
Other Study ID Numbers: Methylcobalamin
First Posted: August 9, 2012    Key Record Dates
Last Update Posted: May 20, 2014
Last Verified: May 2014

Keywords provided by Derek Obersby, University of West London:
Hyperhomocysteinemia
Methylcobalamin
Cardiovascular disease
Plasma total homocysteine
Vegetarians

Additional relevant MeSH terms:
Vitamin B 12 Deficiency
Vitamin B Deficiency
Deficiency Diseases
Vitamins
Vitamin B 12
Hydroxocobalamin
Vitamin B Complex
Hyperhomocysteinemia
Avitaminosis
Malnutrition
Nutrition Disorders
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Malabsorption Syndromes
Metabolic Diseases
Micronutrients
Growth Substances
Physiological Effects of Drugs
Hematinics